Mycophenolic acid sodium (Synonyms: Mycophenolate sodium)

Cat. No.: HY-B0421A: FAQs
Data Sheet Handling Instructions

Molarity Calculator

Mycophenolic acid sodium is a potent uncompetitive inosine monophosphate dehydrogenase (IMPDH) inhibitor with an EC₅₀ of 0.24 µM. Mycophenolic acid sodium demonstrates antiviral effects against a wide range of RNA viruses including influenza. Mycophenolic acid sodium is an immunosuppressive agent. Antiangiogenic and antitumor effects.

For research use only. We do not sell to patients.

Mycophenolic acid sodium Chemical Structure

CAS No. : 37415-62-6

Size		Stock
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Mycophenolic acid sodium:

Other Forms of Mycophenolic acid sodium:

Mycophenolic acid In-stock

7 Publications Citing Use of MCE Mycophenolic acid sodium

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Antibiotic Isoform Specific Products:

View All Isoforms

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

Human Endogenous Metabolite

In Vitro

Mycophenolic acid sodium demonstrates antiviral effects against a wide range of RNA viruses including influenza, dengue virus, Zika virus, rotavirus, CCHFV, and hantavirus^[1].
IMPDH is the rate-limiting enzyme in the de novo synthesis of guanosine nucleotides^[2].
Mycophenolic acid (0.01-1 μM; 72 hours) sodium exhibits preferential antiproliferative activity against the endothelial cells and fibroblasts. Endothelial cells are most sensitive cells to Mycophenolic acid treatment with an IC₅₀ <500 nM for antimitotic effects^[2].
Fibroblasts are also prone to Mycophenolic acid-induced cell cycle inhibition but exhibit a higher IC₅₀ (<1 μM) compared with endothelial cells. The two human tumor cell lines A549 non-small cell lung cancer cells and PC3 prostate cancer cells show intermediate sensitivity with an IC₅₀ >1 μM. U87 glioblastoma cells are resistant against Mycophenolic acid sodium treatment up to 1 μM^[2].
Mycophenolic acid (0.05-2 μM; 18 hours) sodium exhibits a dose-dependent down-regulation of HDAC2 and MYC, whereas up-regulates NDRG1^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[2]

Cell Line:	Primary isolated human dermal microvascular endothelial cells (HDMVEC) , fibroblasts, U87 glioblastoma cells, PC3 prostate cancer cells, A549 non-small cell lung cancer cells.
Concentration:	0.01, 0.1, 1 μM
Incubation Time:	72 hours
Result:	Exhibited preferential antiproliferative activity against HDMVEC and fibroblasts. Whereas U87 glioblastoma cells were resistant to treatment, A549 non-small cell lung cancer and PC3 prostate cancer cells showed intermediate sensitivity.

Western Blot Analysis^[2]

Cell Line:	HDMVEC
Concentration:	0, 0.05, 0.1, 0.5, 1, and 2 μM
Incubation Time:	18 hours
Result:	Showed a dose-dependent regulation of HDAC2, MYC, and NDRG1.

In Vivo

Mycophenolic acid (120 mg/kg; oral gavage; b.i.d.) sodium exerts its antitumor effects via modulation of the tumor microenvironment, U87 tumor growth is markedly inhibited in vivo in BALB/c nude mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Athymic 8-week-old, 20 g BALB/c nu/nu mice bearing Mycophenolic acid-resistant human U87 tumor model^[2]
Dosage:	120 mg/kg MMF (the morpholinoethyl ester prodrug of Mycophenolic acid)
Administration:	Oral gavage; b.i.d.
Result:	MMF (the morpholinoethyl ester prodrug of Mycophenolic acid) significantly inhibited tumor growth (∼70% after day 14 after tumor implantation) in MMF-treated versus control mice. Microvessel density (CD31 staining) and pericyte coverage determined by α-smooth muscle actin staining were markedly reduced in MMF-treated versus control tumors (44% and 78%, respectively).

Clinical Trial

Molecular Weight

342.32

Formula

C₁₇H₁₉NaO₆

CAS No.

37415-62-6

SMILES

O=C(O[Na])CC/C(C)=C/CC1=C(O)C2=C(COC2=O)C(C)=C1OC

Structure Classification

Ketones, Aldehydes, Acids

Initial Source

Endogenous metabolite

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Stephen R Welch, et al. Screening and Identification of Lujo Virus Inhibitors Using a Recombinant Reporter Virus Platform. Viruses. 2021 Jun 28;13(7):1255. [Content Brief]

[2]. Sophie Domhan, et al. Molecular mechanisms of the antiangiogenic and antitumor effects of mycophenolic acid. Mol Cancer Ther. 2008 Jun;7(6):1656-68. [Content Brief]

Mycophenolic acid sodium Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks